Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 8/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 6/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17936828 | 0.84 | MAP4K4 (0.39) | MEN1KMT2ANR1H2NAMPTHSD11B1 | |
| SCHEMBL17926262 | 0.84 | MAP4K4 (0.39) | MEN1KMT2ANR1H2NAMPTHSD11B1 | |
| SCHEMBL17936822 | 0.84 | MAP4K4 (0.39) | MEN1KMT2ANR1H2NAMPTHSD11B1 | |
| SCHEMBL28883948 | 0.81 | NR1H2 (0.39) | MEN1KMT2ANR1H2NAMPTHSD11B1 | |
| SCHEMBL19781607 | 0.72 | MEN1 (0.37) | MEN1KMT2ANR1H2HSD11B1 | |
| SCHEMBL19781282 | 0.72 | MEN1 (0.37) | MEN1KMT2ANR1H2HSD11B1 | |
| SCHEMBL12307403 | 0.71 | NR1H2 (0.52) | MEN1KMT2ANR1H2 | |
| SCHEMBL2081318 | 0.70 | MEN1 (0.53) | MEN1KMT2ANAMPTHDAC8 | |
| SCHEMBL3929271 | 0.70 | MEN1 (0.53) | MEN1KMT2ANAMPTHDAC8 | |
| SCHEMBL31359949 | 0.70 | MEN1 (0.53) | MEN1KMT2ANAMPTHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025016899-A1 | SPIROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2025-01-23 | — | — | WO | disclosed |